Center

Center Laboratories is a leading Taiwan-based pharmaceutical company that has transformed into a professional biotechnology venture holdings group and incubator. Founded in 1959, the company established a dominant market position in oral liquid drug manufacturing before repositioning itself to focus on specialty pharmaceuticals and the incubation of high-growth biotech startups in the Asia-Pacific region. Its primary therapeutic areas of interest include central nervous system (CNS) disorders, metabolic diseases, and pediatric healthcare. The company's lead internal clinical candidate, CS02, is a novel anti-diabetic small molecule that has successfully completed Phase 2 trials, demonstrating a significant impact on HbA1c levels. Through its Center Ventures division, the company manages a diverse portfolio of investments in firms such as Lumosa Therapeutics and Ausnutria Dairy, leveraging its deep expertise in manufacturing and regulatory affairs to bring innovative therapies to market.